Search

everythinglearnresearchcommunity

for

Search:↓

A user reported significant hair regrowth using only 1mg finasteride daily over 3.5 years, with no side effects. They stressed patience and consistency, seeing noticeable results after two years.

Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.

A 23-year-old shared his successful hair regrowth journey, highlighting the importance of correcting vitamin deficiencies and using oral minoxidil and finasteride, later switching to topical minoxidil. He emphasized the effectiveness of addressing basic health issues and staying consistent with treatments.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

The user experienced increased hair density after starting 1mg finasteride in February and 2.5mg oral minoxidil two months ago, along with 10mg biotin daily. They initially used topical minoxidil but switched to oral due to application difficulties and have seen improvements without significant side effects.

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

The user reported significant improvement in hair thickness and color in the crown area after 3 months on Dutasteride 2.5 mg and oral Minoxidil 5 mg, with temporary side effects that resolved. They switched from Finasteride to Dutasteride due to lack of results with the former.

The user experienced significant hair improvement after switching from topical to oral treatments, using finasteride, minoxidil, and biotin. They reported no major side effects, except for slightly thicker hair on their hands.

Oral minoxidil, finasteride, and dutasteride are being used to treat hair loss, but results are limited, leading to consideration of a hair transplant. The user plans to continue medication for another year before deciding on further action.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.